Brief: Compugen Doses First Patient In Triple Immunotherapy Combination COM701, COM902 And Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study
22/06/2023 12:13
June 22 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN DOSES FIRST PATIENT IN TRIPLE IMMUNOTHERAPY
COMBINATION
COM701, COM902 AND PEMBROLIZUMAB PLATINUM RESISTANT OVARIAN
CANCER PROOF-OF-CONCEPT STUDY
* COMPUGEN LTD - INITIAL FINDINGS EXPECTED BY END OF 2023
Source text for Eikon: ID:nPn3ldk08a
Further company coverage: CGEN.TA
((reuters.briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025